{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-124538","form_type":"8-K","ticker":"DCTH","cik":"0000872912","company_name":"DELCATH SYSTEMS, INC.","filed_at":"2025-05-22T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.532621+00:00","generated_at":"2026-05-20T19:52:46.175539+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Delcath issues 2025 revenue guidance of $94-98M, plans to enter Medicaid drug rebate agreement","bullets":["Revenue guidance $94-98M, >150% YoY growth.","Gross margin 83-85%; positive adjusted EBITDA and cash flow each quarter in 2025.","Plans to enter NDRA with CMS, effective Q3 2025, expanding Medicaid/340B access.","CEO expects HEPZATO treatment volume to increase at least 200% in 2025 vs 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-124538","json":"https://secwatch.observer/filing/0001193125-25-124538.json","markdown":"https://secwatch.observer/filing/0001193125-25-124538.md","text":"https://secwatch.observer/filing/0001193125-25-124538.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/872912/000119312525124538/0001193125-25-124538-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/872912/000119312525124538/d946891d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T19:52:46.175539+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}